MAIA Biotechnology, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Fair Value of Financial Liabilities (Tables)

Fair Value of Financial Liabilities (Tables)

12 Months Ended

Dec. 31, 2022

Schedule of Fair Value Measurements of Embedded Derivative Liabilities and Warrant Liabilities

Financial liabilities consisting of warrant liabilities measured at fair value on a recurring basis are summarized below. The fair value of the warrant liabilities recorded are as follows:


	Fair value at December 31, 2022
	Total		Level 1		Level 2		Level 3
Liabilities:
Warrant liability		245,341		—		—		245,341
Total liabilities	$	245,341	$	—	$	—	$	245,341

Schedule of Changes in Fair Value of the Derivative Liabilities and Warrant Liabilities

The table below provides a summary of the changes in fair value of the derivative liabilities related to Convertible notes using significant unobservable inputs (level 3):


	Year Ended December 31,
Derivative liabilities:	2022		2021
Balance, beginning of period	$	—	$	127,000
Derivative liability on convertible notes payable		—		2,821,000
Loss (Gain) on fair value of embedded features		—		203,000
Extinguishment of derivative liability in connection with debt conversion		—		(3,151,000	)
Balance, end of period	$	—	$	—

The table below provides a summary of the changes in fair value of the warrant liabilities measured on a recurring basis using significant unobservable inputs (Level 3):


	Years Ended December 31,
Warrant liabilities:	2022			2021
Balance, beginning of period	$	—		$	85,260
Warrant liability		343,735			320,460
(Gain) loss on fair value of warrant liability		(98,394	)		1,546,280
Reclassification of warrant liability to equity		—			(1,952,000	)
Balance, end of period	$	245,341		$	—